新冠肺炎患者的死亡率与近期肺炎支原体感染的关系。
Association of mortality and recent Mycoplasma pneumoniae infection in COVID-19 patients.
机构信息
Department of Medicine, Hoboken University Medical Center, Hoboken, New Jersey, USA.
Department of Pediatrics, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
出版信息
J Med Virol. 2021 Feb;93(2):1180-1183. doi: 10.1002/jmv.26467. Epub 2020 Sep 29.
To compare characteristics and outcomes of patients who had COVID-19 with Mycoplasma pneumoniae immunoglobulin M (IgM) antibodies to those without M. pneumoniae antibodies. We retrospectively reviewed cases admitted over a 4-week period between 17 March 2020 and 14 April 2020 to the Hoboken University Medical Center, NJ, USA. We compared the outcomes of COVID-19 patients who were positive for M. pneumoniae IgM with those who were negative for M. pneumoniae IgM. The primary outcome was mortality. The adjusted odds ratio was calculated after controlling for baseline differences. Of 139 patients admitted with COVID-19, 79 were positive for M. pneumoniae IgM. The mortality among those who were M. pneumoniae IgM positive was significantly higher (adjusted odds ratio: 2.28, 95% confidence interval: 1.03 to 5.03) compared with those who were M. pneumoniae IgM negative. Patients with coinfection (COVID-19 and mycoplasma) have higher mortality compared with patients with just COVID-19 disease.
比较 COVID-19 患者与肺炎支原体免疫球蛋白 M（IgM）抗体阳性和阴性患者的特征和结局。我们回顾性分析了 2020 年 3 月 17 日至 4 月 14 日期间美国新泽西州霍博肯大学医学中心住院的 4 周内的病例。我们比较了肺炎支原体 IgM 阳性的 COVID-19 患者与肺炎支原体 IgM 阴性患者的结局。主要结局是死亡率。在控制基线差异后计算了调整后的优势比。在 139 名因 COVID-19 住院的患者中，有 79 名肺炎支原体 IgM 阳性。肺炎支原体 IgM 阳性患者的死亡率明显更高（调整后的优势比：2.28，95%置信区间：1.03 至 5.03），而肺炎支原体 IgM 阴性患者的死亡率则较低。合并感染（COVID-19 和支原体）的患者与仅患有 COVID-19 疾病的患者相比，死亡率更高。
Zotero 插件